Colinz Laboratories

Colinz Laboratories Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Colinz Laboratories (531210.BO) as of Nov 2, 2026 is 2.86. In the previous year, Net Debt to Free Cash Flow Ratio was -6.21 — a change of -146.05% (higher).

Net Debt/FCF

2.86

YoY

-146.05%

Last updated:

Net Debt to Free Cash Flow Ratio of Colinz Laboratories is 2025 2.86 . Net Debt to Free Cash Flow Ratio of Colinz Laboratories was 2024 -6.21 . It decreases by -146.05% higher compared to the previous year.

The Colinz Laboratories Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2018
-4.31 INR
Jan 1, 2019
-11.36 INR
Jan 1, 2020
-4.13 INR
Jan 1, 2021
-1.84 INR
Jan 1, 2022
-10.99 INR
Jan 1, 2023
-13.54 INR
Jan 1, 2024
-6.21 INR
Jan 1, 2025
2.86 INR
The Colinz Laboratories Net Debt/FCF history
YEARNet Debt/FCFYoY
2.86-146.05%
-6.21-54.10%
-13.54+23.19%
-10.99+496.00%
-1.84-55.35%
-4.13-63.63%
-11.36+163.70%
-4.31-80.34%
-21.91-1,714.34%
1.36-97.32%
50.62+757.80%
5.90—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Colinz Laboratories Stock analysis

What does Colinz Laboratories do? Colinz Laboratories Ltd manufactures pharmaceutical formulations including tablets, capsules, granules, liquid orals, injectables, ointments, and creams. The company markets allopathic and ayurvedic products targeting hypertension, cholesterol, diabetes, piles, pyrexia, and malaria treatments for physicians. Gynecologists receive specialized products for morning sickness, infertility, IUGR, and pregnancy maintenance. Additional offerings include hematinic, antispasmodic, anti-inflammatory/anti-allergic tablets, capsules, gel, and medicated shampoo. Products are sold across Maharashtra, Karnataka, Andhra Pradesh, Gujarat, Rajasthan, Madhya Pradesh, Chhattisgarh, and West Bengal through the company's own marketing team. The firm's revenue streams come from direct sales to healthcare professionals and pharmacies within its operational states. Physicians prescribe products for chronic conditions like hypertension and diabetes, while gynecologists utilize specialized treatments for pregnancy-related issues. The company's product portfolio spans both conventional allopathic medicines and traditional ayurvedic formulations, catering to diverse medical needs. Marketing efforts focus on state-specific distribution through dedicated in-house sales staff. Colinz Laboratories Ltd serves the pharmaceutical market segment with a clear focus on regional healthcare providers. Its product range addresses common health concerns such as cardiovascular issues, metabolic disorders, and pregnancy care. The company's strategy involves direct engagement with medical practitioners to promote its formulations, ensuring consistent market presence in key Indian states without external partnerships or third-party distribution channels. Colinz Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Colinz Laboratories stock

Net Debt to Free Cash Flow Ratio of Colinz Laboratories is 2.86 in 2025.

Net Debt to Free Cash Flow Ratio of Colinz Laboratories changed from -6.21 to 2.86, representing a -146.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Colinz Laboratories since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Colinz Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Colinz Laboratories

All Key Metrics — Colinz Laboratories